Arvinas: Barclays Sees 110% Price Potential - Experts See Multiple Opportunities in Oncology and Neurology
Reading Time: 2 minutes
Arvinas Inc. (ARVN) is a biotechnology company developing a unique technology called PROTACs (PROteolysis TArgeting Chimeras). Unlike traditional drugs that block proteins, PROTACs utilize the body's own disposal system to specifically degrade and remove disease-causing proteins. They act as a type of "molecular adhesive" that connects a harmful protein to a natural disposal system of the cell. Cancer Treatment Pipeline Arvinas is heavily focused on developing cancer therapies. The most promising candidate in this area is Vepdegestrant (ARV-471),...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
